SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amid mixed sentiment, with some community members highlighting its infrastructure role and potential for developers, while others express frustration with its price performance and call it a "scam token." Discussions also revolve around the upcoming Neura L1 blockchain and its potential impact on the token's utility and value, with some hoping for a coin burn mechanism to drive demand.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA.X) is trending amid anticipation for its mainnet launch and excitement surrounding its potential to revolutionize traditional finance. Community members highlight Keeta's anchor technology and partnerships as key drivers for unifying blockchains. The recent listing on exchanges like Coinbase is also fueling positive sentiment, with some suggesting it will replace other blockchains.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to recent financial guidance updates and the completed acquisition of Melinta Therapeutics, with the community actively discussing the potential impacts of the acquisition and future revenue projections. Some are concerned about potential executive stock sales, while others are optimistic about the company's growth and the potential for a short squeeze. Discussions also revolve around DefenCath's adoption rates and potential CMS policy changes.

Trump For President

The TRUMP.X cryptocurrency is trending amid discussions about its potential connection to Donald Trump's political activities and the launch of new related tokens. The community is actively debating the coin's utility, speculating on its future value, and expressing concerns about market manipulation. Some users are also referencing Trump's recent activities and their potential impact on the coin's performance.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors discuss its aggressive capital allocation strategy amid strong gold prices, including a massive buyback program and significant shareholder returns. Community members are weighing the impact of these factors, alongside potential cost-cutting measures and unusual options activity, on the company's future performance and stock price, with some highlighting its potential for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scilex Holding Company (SCLX) on Thursday said that its majority-owned subsidiary, Semnur Pharmaceuticals, and Denali Capital Acquisition Corp (DECA) have entered into a purchase agreement with an investor for a $20 million private placement.The proceeds of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/10161/pdf">agreement</a> will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain. Lumbosacral radicular pain, often referred to as sciatica, is a pain that radiates along the sciatic nerve, which extends from the lower back down the leg.On Stocktwits, retail sentiment around Scilex remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels. <a href="https://stocktwits.com/symbol/SCLX">SCLX stock</a> is trading 0.5% lower in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:567/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_7_24_17_AM_png_36aea133ff.webp" alt="SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="567" height="60"><figcaption>SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>Semnur and special purpose acquisition company (SPAC) Denali entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/9226/pdf">plan of merger</a> on Aug. 30, 2024, for a proposed business combination, among Semnur, the SPAC, and the SPAC's unit Denali Merger Sub Inc. This provided for a pre-transaction equity value of Semnur at $2.5 billion.&nbsp;Under the deal, the combined company will be renamed Semnur Pharmaceuticals, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol “SMNR”. The combination is now expected to close in September 2025.An investor has agreed to purchase an aggregate of 1.25 million shares of common stock of the combined company following the consummation of the merger transaction, Scilex said. The purchase price for the placement is $16.00 per share, for an aggregate purchase price of $20 million.The closing of the financing is subject to customary conditions and is expected to occur immediately following the consummation of the business combination, Scilex said.The company also said that CEO Jaisim Shah resigned as Scilex CEO and will now serve as chief executive and President of Semnur. Henry Ji, who currently serves as Executive Chairman of Scilex, was appointed as Scilex’s new CEO and President and has assumed all of the duties formerly performed by Shah, the company said.SCLX stock is up by 18% this year and down by 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/two-players-quietly-took-over-bitcoin-mining-power-heres-why-it-matters/chsSu9WRdi5">Two Players Quietly Took Over Bitcoin’s Mining Power — Here’s Why It Matters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

The proceeds of the agreement will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain.

Equity

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt PR Newswire NEW YORK, Oct. 7, 2024 NEW...

Scilex Holding Co. (SCLX), a relatively under-the-radar player in the non-opioid pain management space, has unexpectedly captured the attention of retail investors. The company experienced a staggering 41.78% increase in retail followers on Stocktwits over the past month, despite a 21% decline in its share price.However, the initial bullish sentiment has waned, with Stocktwits sentiment flipping to bearish (36/100) and message volumes surging. This shift suggests growing investor skepticism amidst recent company developments.<figure class="image"><img style="aspect-ratio:1316/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SCLX_Sentiment_and_message_score_Aug_1_f79a43cdac.png" alt="SCLX Sentiment and message score Aug 1.png" width="1316" height="306"><figcaption>SCLX Sentiment and message score Aug 1</figcaption></figure>The surge in retail interest can be attributed to several factors. Primarily, the announcement of a potential $2 billion deal for its subsidiary, Semnur Pharmaceuticals, to go public through a SPAC merger with Denali Capital Acquisition Corp (DECA) has generated excitement. The proceeds from this deal are earmarked for the development of SP-102, a key drug candidate in late-stage trials.Additionally, Scilex had reported preliminary Q2 net sales above estimates, indicating revenue growth. However, a significant decline in cash and cash equivalents raised concerns.The company also entered into a collaboration agreement with ACEA for the potential expansion of its ZTlido treatment, used to help relieve nerve pain after shingles, in the Greater China region.While July saw continued sales growth for ZTlido, the pace of growth slowed compared to the previous month. This, coupled with the overall bearish sentiment and declining cash reserves, seems to have tempered initial enthusiasm.With Q2 earnings report scheduled for August 9th after market hours, investors will be closely watching for further clarity on the company's financial health and the progress of its key initiatives.Photo via Vecteezy

Small-Cap Scilex Drew Biggest Jump In Retail Following For July: What Drove It?

Retail investors flocked to Scilex, drawn by news about a lucrative SPAC deal for its unit, declining cash reserves and slowing sales growth.

Scilex Holding Settles Lawsuit, Continues Litigation Against Ex-President

Scilex Holding Company (SCLX) has provided an update. Scilex Holding Company's subsidiary and Sorrento Therapeutics filed a lawsuit alleging breach...

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend

PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex ), an innovative revenue-generating company focused on acquiring, developing and commercializing...

Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients

PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company ), an innovative revenue-generating company focused on acquiring, developing and...

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba  Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed

Seek approval from the FDA for the modification of the Gloperba label to include its ability to utilize dosing flexibility of liquid formulation to address unmet medical needs and provide specific...

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchici

PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company ), an innovative revenue-generating company focused on acquiring, developing and...

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex ), an innovative revenue-generating company focused on acquiring, developing and commercializing...

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB  Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB  for Acute Treatment of Migraine With or Without Aura in 

ELYXYB is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it...

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

SCLX
Scilex Holding Company

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SCLX News

SCLX Scilex Holding Company